Literature DB >> 15463891

Early intervention and prevention of lung disease in cystic fibrosis: a European consensus.

Gerd Döring1, Niels Hoiby.   

Abstract

In patients with cystic fibrosis (CF), early intervention and prevention of lung disease is of paramount importance. Principles to achieve this aim include early diagnosis of CF, regular monitoring of the clinical status, various hygienic measures to prevent infection and cross-infection, early use of antibiotic courses in patients with recurrent or continuous bacterial colonisation and appropriate use of chest physiotherapy.

Entities:  

Mesh:

Year:  2004        PMID: 15463891     DOI: 10.1016/j.jcf.2004.03.008

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  58 in total

1.  Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

Authors:  Michael W Konstan; Patrick A Flume; Matthias Kappler; Raphaël Chiron; Mark Higgins; Florian Brockhaus; Jie Zhang; Gerhild Angyalosi; Ellie He; David E Geller
Journal:  J Cyst Fibros       Date:  2010-11-12       Impact factor: 5.482

Review 2.  Newborn screening for cystic fibrosis: do we need a second IRT?

Authors:  J F Price
Journal:  Arch Dis Child       Date:  2006-03       Impact factor: 3.791

3.  Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections.

Authors:  Shalini Yapa; Jian Li; Christopher J H Porter; Roger L Nation; Kashyap Patel; Michelle P McIntosh
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

Review 4.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 5.  Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis.

Authors:  Helle Krogh Johansen; Peter C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2015-08-23

6.  Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration.

Authors:  Shalini Yapa; Jian Li; Kashyap Patel; John W Wilson; Michael J Dooley; Johnson George; Denise Clark; Susan Poole; Elyssa Williams; Christopher J H Porter; Roger L Nation; Michelle P McIntosh
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 7.  Inhaled antibiotics for lower airway infections.

Authors:  Bradley S Quon; Christopher H Goss; Bonnie W Ramsey
Journal:  Ann Am Thorac Soc       Date:  2014-03

8.  Potent antibacterial antisense peptide-peptide nucleic acid conjugates against Pseudomonas aeruginosa.

Authors:  Anubrata Ghosal; Peter E Nielsen
Journal:  Nucleic Acid Ther       Date:  2012-10       Impact factor: 5.486

9.  Rehabilitation Programs for Cystic Fibrosis - View from a CF Center.

Authors:  M Griese; P Busch; D Caroli; B Mertens; C Eismann; M Harari; H Staudter; M Kappler
Journal:  Open Respir Med J       Date:  2010-01-07

10.  Review of recombinant human deoxyribonuclease (rhDNase) in the management of patients with cystic fibrosis.

Authors:  Tacjana Pressler
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.